Masse E - Search Results

1

Early Actions of Anti-Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood Vessels.

Sitohy B, Chang S, Sciuto TE, Masse E, Shen M, Kang PM, Jaminet SC, Benjamin LE, Bhatt RS, Dvorak AM, Nagy JA, Dvorak HF. Sitohy B, et al. Among authors: masse e. Am J Pathol. 2017 Oct;187(10):2337-2347. doi: 10.1016/j.ajpath.2017.06.010. Epub 2017 Jul 21. Am J Pathol. 2017. PMID: 28736316 Free PMC article.

2

Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation.

Nagy JA, Masse EM, Herzberg KT, Meyers MS, Yeo KT, Yeo TK, Sioussat TM, Dvorak HF. Nagy JA, et al. Among authors: masse em. Cancer Res. 1995 Jan 15;55(2):360-8. Cancer Res. 1995. PMID: 7812969

3

Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions.

Yeo KT, Wang HH, Nagy JA, Sioussat TM, Ledbetter SR, Hoogewerf AJ, Zhou Y, Masse EM, Senger DR, Dvorak HF, et al. Yeo KT, et al. Among authors: masse em. Cancer Res. 1993 Jun 15;53(12):2912-8. Cancer Res. 1993. PMID: 8504432

4

Vascular targeting of solid and ascites tumours with antibodies to vascular endothelial growth factor.

Ke-Lin, Qu-Hong, Nagy JA, Eckelhoefer IA, Masse EM, Dvorak AM, Dvorak HF. Ke-Lin, et al. Among authors: masse em. Eur J Cancer. 1996 Dec;32A(14):2467-73. doi: 10.1016/s0959-8049(96)00391-7. Eur J Cancer. 1996. PMID: 9059335 No abstract available.

5

Pathogenesis of ascites tumor growth: fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity.

Nagy JA, Meyers MS, Masse EM, Herzberg KT, Dvorak HF. Nagy JA, et al. Among authors: masse em. Cancer Res. 1995 Jan 15;55(2):369-75. Cancer Res. 1995. PMID: 7812970

6

Exchange of macromolecules between plasma and peritoneal cavity in ascites tumor-bearing, normal, and serotonin-injected mice.

Nagy JA, Herzberg KT, Masse EM, Zientara GP, Dvorak HF. Nagy JA, et al. Among authors: masse em. Cancer Res. 1989 Oct 1;49(19):5448-58. Cancer Res. 1989. PMID: 2475250

7

Mesothelial cell-mediated gene therapy: feasibility of an ex vivo strategy.

Nagy JA, Shockley TR, Masse EM, Harvey VS, Jackman RW. Nagy JA, et al. Among authors: masse em. Gene Ther. 1995 Aug;2(6):393-401. Gene Ther. 1995. PMID: 7584114

8

Systemic delivery of a recombinant protein by genetically modified mesothelial cells reseeded on the parietal peritoneal surface.

Nagy JA, Shockley TR, Masse EM, Harvey VS, Hoff CM, Jackman RW. Nagy JA, et al. Among authors: masse em. Gene Ther. 1995 Aug;2(6):402-10. Gene Ther. 1995. PMID: 7584115

9

Enhancement of the functional repertoire of the rat parietal peritoneal mesothelium in vivo: directed expression of the anticoagulant and antiinflammatory molecule thrombomodulin.

Jackman RW, Stapleton TD, Masse EM, Harvey VS, Meyers MS, Shockley TR, Nagy JA. Jackman RW, et al. Among authors: masse em. Hum Gene Ther. 1998 May 1;9(7):1069-81. doi: 10.1089/hum.1998.9.7-1069. Hum Gene Ther. 1998. PMID: 9607418

10

Modulation of transgene expression in mesothelial cells by activation of an inducible promoter.

Hoff CM, Cusick JL, Masse EM, Jackman RW, Nagy JA, Shockley TR. Hoff CM, et al. Among authors: masse em. Nephrol Dial Transplant. 1998 Jun;13(6):1420-9. doi: 10.1093/ndt/13.6.1420. Nephrol Dial Transplant. 1998. PMID: 9641171

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

164 results

Search Page

Filters